Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.

Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, Hagen CE, van Harten AC, Knopman DS, Jack CR Jr, Petersen RC, Mielke MM.

JAMA Neurol. 2019 Feb 1;76(2):187-193. doi: 10.1001/jamaneurol.2018.3459.

2.

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.

Pereira JB, Westman E, Hansson O; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2017 Oct;58:14-29. doi: 10.1016/j.neurobiolaging.2017.06.002. Epub 2017 Jun 17.

PMID:
28692877
3.

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2016 Jan;73(1):60-7. doi: 10.1001/jamaneurol.2015.3037.

4.

Neurogranin as a predictor of memory and executive function decline in MCI patients.

Headley A, De Leon-Benedetti A, Dong C, Levin B, Loewenstein D, Camargo C, Rundek T, Zetterberg H, Blennow K, Wright CB, Sun X; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 6;90(10):e887-e895. doi: 10.1212/WNL.0000000000005057. Epub 2018 Feb 2.

5.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
6.

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.

Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Nov;72(11):1275-80. doi: 10.1001/jamaneurol.2015.1867.

7.

Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.

Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, Machulda MM, Roberts RO, Jack CR Jr, Petersen RC, Dage JL.

JAMA Neurol. 2017 Sep 1;74(9):1073-1080. doi: 10.1001/jamaneurol.2017.1359.

8.

Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.

Sanfilippo C, Forlenza O, Zetterberg H, Blennow K.

J Neural Transm (Vienna). 2016 Dec;123(12):1443-1447. doi: 10.1007/s00702-016-1597-3. Epub 2016 Aug 16.

PMID:
27531278
9.

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.

Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR.

Alzheimers Res Ther. 2018 Mar 20;10(1):33. doi: 10.1186/s13195-018-0362-2.

10.

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.

Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.

JAMA Neurol. 2017 Dec 1;74(12):1492-1501. doi: 10.1001/jamaneurol.2017.2814.

11.

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

Gangishetti U, Christina Howell J, Perrin RJ, Louneva N, Watts KD, Kollhoff A, Grossman M, Wolk DA, Shaw LM, Morris JC, Trojanowski JQ, Fagan AM, Arnold SE, Hu WT.

Alzheimers Res Ther. 2018 Sep 25;10(1):98. doi: 10.1186/s13195-018-0426-3.

12.

Neurofilament relates to white matter microstructure in older adults.

Moore EE, Hohman TJ, Badami FS, Pechman KR, Osborn KE, Acosta LMY, Bell SP, Babicz MA, Gifford KA, Anderson AW, Goldstein LE, Blennow K, Zetterberg H, Jefferson AL.

Neurobiol Aging. 2018 Oct;70:233-241. doi: 10.1016/j.neurobiolaging.2018.06.023. Epub 2018 Jun 28.

13.

Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.

Gleason CE, Norton D, Anderson ED, Wahoske M, Washington DT, Umucu E, Koscik RL, Dowling NM, Johnson SC, Carlsson CM, Asthana S; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;61(1):79-89. doi: 10.3233/JAD-170498.

14.

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN.

Alzheimers Res Ther. 2016 Apr 27;8(1):17. doi: 10.1186/s13195-016-0182-1.

15.

Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.

Wallin A, Göthlin M, Gustavsson M, Zetterberg H, Eckerström C, Blennow K, Edman A, Lind K, Nordlund A, Rolstad S.

Dement Geriatr Cogn Disord. 2011;32(3):193-7. doi: 10.1159/000333034. Epub 2011 Nov 3.

PMID:
22057225
16.

Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, Machulda MM, Graff-Radford J, Knopman DS, Jack CR Jr, Petersen RC, Kern S.

Alzheimers Dement. 2019 Nov;15(11):1437-1447. doi: 10.1016/j.jalz.2019.07.009. Epub 2019 Oct 23.

PMID:
31668594
17.

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

Sjögren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A.

J Neurosci Res. 2001 Nov 1;66(3):510-6.

PMID:
11746370
18.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2016 Oct 4;8(10):1184-1196. doi: 10.15252/emmm.201606540. Print 2016 Oct.

19.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
20.

Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.

Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Dubois B, Floris R, Garaci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2018 Apr;14(4):492-501. doi: 10.1016/j.jalz.2017.11.015. Epub 2018 Jan 9.

PMID:
29328927

Supplemental Content

Support Center